{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:17:48Z","timestamp":1770967068531,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T00:00:00Z","timestamp":1433721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["U01CA076576"],"award-info":[{"award-number":["U01CA076576"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["T32CA165998"],"award-info":[{"award-number":["T32CA165998"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Single\u2010agent post\u2010autologous transplant maintenance therapy with lenalidomide is standard of care for patients with multiple myeloma. The tolerability and effectiveness of combination post\u2010transplant maintenance therapy is unknown, so we investigated lenalidomide and vorinostat (suberoylanilide hydroxamic acid) in this setting, hypothesizing that the regimen would be well tolerated and associated with an improved post\u2010transplant response. This trial followed a standard 3\u00a0\u00d7\u00a03 dose escalation phase 1 design. Vorinostat was administered beginning day +90 post\u2010haematopoietic stem cell transplantation for days 1\u20137 and 15\u201321, and lenalidomide was started at 10\u00a0mg days 1\u201321, both on a 28\u2010d cycle. The primary endpoint was maximum tolerated dose and dose limiting toxicities were assessed during the first cycle. Treatment was well tolerated in 16 enrolled patients. During Cycle 1, the most common toxicities included cytopenias, gastrointestinal complaints and fatigue. Seven patients improved their transplant response after starting combination therapy. The median follow\u2010up was 38\u00b74\u00a0months, and the median progression\u2010free survival and overall survival have yet to be reached. This oral post\u2010transplant maintenance regimen was well tolerated. This is the first trial to publish results on the use of a histone deacetylase inhibitor in the maintenance setting, and it provides rationale for the ongoing randomized trial in maintenance (ISRCTN 49407852).<\/jats:p><jats:p>Trial Registration: NCT00729118<\/jats:p>","DOI":"10.1111\/bjh.13527","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T01:35:57Z","timestamp":1433986557000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma"],"prefix":"10.1111","volume":"171","author":[{"given":"Douglas W.","family":"Sborov","sequence":"first","affiliation":[{"name":"Hematology\/Oncology Fellowship Department of Internal Medicine The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don M.","family":"Benson","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nita","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy A.","family":"Bowers","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Humphries","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Devine","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2850"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01384.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1422"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70398-X"},{"key":"e_1_2_8_9_1","first-page":"399","article-title":"Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T\u2010cell lymphoma patients: updated results of the phase IIb multicenter clinical trial","volume":"108","author":"Duvic M.","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-025999"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkj462"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05286.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023075"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.15.1701"},{"key":"e_1_2_8_15_1","first-page":"3034","article-title":"Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front\u2010line therapy for patients with multiple myeloma (MM): initial results of a phase 1 study","volume":"116","author":"Kaufman J.L.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235663"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052702999"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.231"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536759100"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.335"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0561"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.013"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.236"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701817258"},{"key":"e_1_2_8_27_1","first-page":"3065","article-title":"Vorinostat overcomes lenalidomide\u2010dexamethasone and lenalidomide\u2010bortezomib\u2010dexamethasone resistance in relapsed\/refractory multiple myeloma","volume":"116","author":"Siegel D.S.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_28_1","first-page":"480","article-title":"Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial","volume":"118","author":"Siegel D.S.","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.1"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0599"},{"key":"e_1_2_8_31_1","first-page":"759","article-title":"ACY\u20101215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM)","volume":"122","author":"Vogl D.T.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_32_1","first-page":"3190","article-title":"ACY\u20101215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and dexamethasone (dex), is well tolerated without dose limiting toxicity (DLT) in patients (Pts) with multiple myeloma (MM) at doses demonstrating biologic activity: interim results of a phase 1b trial","volume":"122","author":"Vorhees P.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.07.007"},{"key":"e_1_2_8_34_1","first-page":"152","article-title":"Vorinostat (V) in combination with bortezomib (B), doxorubicin (D) and dexamethasone (D) (VBDD) in patients with refractory or relapsed multiple myeloma: an interim phase I\/II analysis","volume":"36","author":"Wider D.","year":"2013","journal-title":"Onkologie"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13527","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T18:14:17Z","timestamp":1696356857000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/bjh.13527"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13527","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,8]]},"assertion":[{"value":"2015-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}